Silexion Therapeutics faces Nasdaq delisting notice over minimum shareholders’ equity shortfall

Nasdaq issued a delisting notice on Aug. 18, 2026 over non-compliance with the $2.5 million minimum shareholders’ equity rule.

Shareholders’ equity was $44,000 in the quarterly report for the period ended June 30, 2026.

An appeal to a Nasdaq Hearings Panel is due by Aug. 25, 2026; the company plans to file.

Failure to win the appeal could trigger a trading suspension for ordinary shares and warrants, followed by removal from Nasdaq.